Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: linagliptine 5 mgDrug: linagliptine 5 mg and pioglitazone 30 mg
- Registration Number
- NCT00736099
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
The treatment modalities are determined by the treatment in the blinded trial in which every patient was included previously as BI 1356 in monotherapy (patients in 1218.16 trial), BI 1356 in combination with pioglitazone (patients in 1218.15 trial), BI 1356 added to metformin background (patients in 1218.17 trial) or BI 1356 added to a background therapy of metformin in combination with a sulphonylurea (patients in 1218.18 study)
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2122
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description linagliptin 5 mg linagliptine 5 mg open label linagliptin 5 mg and pioglitazone 30 mg linagliptine 5 mg and pioglitazone 30 mg open label
- Primary Outcome Measures
Name Time Method Number of Patients With Abnormalities in Vital Signs 78 weeks Vital sign abnormalities (any abnormalities found during PE or ECG are reported with adverse events)
Number of Patients With Abnormalities in Haematology: Eosinophils 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 10%.
Frequency of Patients With Adverse Events (AEs) 78 weeks This includes any AEs detected during routine physical examination and electrocardiogram (ECG) procedures.
Frequency of Patients With Investigator-defined Hypoglycaemic Adverse Events 78 weeks Frequency of Patients With Significant Adverse Events Based on Standardised MedDRA Query (SMQ) 78 weeks As significant adverse events are considered: renal Aes (SMQ 'acute renal failure'), hypersensitivity reactions ('anaphylactic reactions' and 'angioedema'), hepatic Aes ('hepatitis, non-infectious', 'hepatic failure, fibrosis, cirrhosis and other liver damage-related conditions', 'liver-related investigations, signs and symptoms', 'cholestasis and jaundice of hepatic origin'), severe cutaneous adverse reactions ('severe cutaneous adverse reaction'), pancreatitis ('acute pancreatitis', 'chronic pancreatitis'').
Frequency of Patients With Adjudication of Cardiac and Cerebrovascular Events 78 weeks Patients reported with cardiac and cerebrovascular events qualified for adjudication by the Clinical Event Committee (CEC)
Number of Patients With Abnormalities in Haematology: Haemoglobin 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 11.5 g/dL for male and as a value less than or equal to 9.5 g/dL for female patients.
Number of Patients With Abnormalities in Haematology: Haematocrit 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than or equal to 32%.
Number of Patients With Abnormalities in Haematology: Red Blood Cell Count 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \* 10\^12/L.
Number of Patients With Abnormalities in Haematology: White Blood Cell Count 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 \* 10\^9/L (decrease) or a value greater than 20.1 \* 10\^9/L (increase).
Number of Patients With Abnormalities in Haematology: Platelets 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as value less than or equal to 75 \* 10\^9/L (decrease) or a value greater than or equal to 700 \* 10\^9/L (increase).
Number of Patients With Abnormalities in Clinical Chemistry: Potassium 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 3 mmol/L (decrease) or a value greater than 5.8 mmol/L (increase).
Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Calcium 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 1.8 mmol/L (decrease) or a value greater than 3 mmol/L (increase).
Number of Patients With Abnormalities in Clinical Chemistry: Alanine Transaminase (ALT) 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.
Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 mg/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Albumin 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 2.5 g/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 11 mg/dL for male and as a value greater than 10 mg/dL for female patients.
Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT) 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.
Number of Patients With Abnormalities in Clinical Chemistry: Lactate Dehydrogenase (LDH) 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.
Number of Patients With Abnormalities in Clinical Chemistry: Amylase 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 1.5 times the upper limit of normal (ULN).
Number of Patients With Abnormalities in Clinical Chemistry: Creatinine 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 1.5 mg/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Sodium 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 130 mmol/L (decrease) or a value greater than 160 mmol/L (increase).
Number of Patients With Abnormalities in Clinical Chemistry: Glucose 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 54 mg/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than 300 mg/dL.
Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.
Number of Patients With Abnormalities in Clinical Chemistry: Aspartate Transaminase (AST) 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 3 times the ULN.
Number of Patients With Abnormalities in Clinical Chemistry: Phosphate 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value less than 0.7 mmol/L (decrease) or a value greater than 1.7 mmol/L (increase).
Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP) 78 weeks For this laboratory parameter, a possibly clinically significant abnormality is defined as a value greater than or equal to 2 times the ULN.
- Secondary Outcome Measures
Name Time Method Change in HbA1c From Baseline to Week 6 Baseline and week 6 Change in HbA1c From Baseline to Week 18 Baseline and week 18 Change in HbA1c From Baseline to Week 30 Baseline and week 30 Change in HbA1c From Baseline to Week 42 Baseline and week 42 Change in HbA1c From Baseline to Week 54 Baseline and week 54 Change in HbA1c From Baseline to Week 66 Baseline and week 66 Change in HbA1c From Baseline to Week 78 Baseline and week 78 Number of Patients With HbA1c<7.0% Over Time 78 weeks Number of Patients With HbA1c<6.5% Over Time 78 weeks Number of Patients With Lowered HbA1c by at Least 0.5% Over Time 78 weeks Change in FPG From Baseline to Week 6 Baseline and week 6 Change in FPG From Baseline to Week 18 Baseline and week 18 Change in FPG From Baseline to Week 30 Baseline and week 30 Change in FPG From Baseline to Week 42 Baseline and week 42 Change in FPG From Baseline to Week 54 Baseline and week 54 Change in FPG From Baseline to Week 66 Baseline and week 66 Change in FPG From Baseline to Week 78 Baseline and week 78
Trial Locations
- Locations (232)
1218.40.10010 Boehringer Ingelheim Investigational Site
🇺🇸Hollywood, Florida, United States
1218.40.10018 Boehringer Ingelheim Investigational Site
🇺🇸Houston, Texas, United States
1218.40.30007 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1218.40.30003 Boehringer Ingelheim Investigational Site
🇬🇷Nikaia, Greece
1218.40.10011 Boehringer Ingelheim Investigational Site
🇺🇸Miami, Florida, United States
1218.40.10001 Boehringer Ingelheim Investigational Site
🇺🇸Walnut Creek, California, United States
1218.40.10016 Boehringer Ingelheim Investigational Site
🇺🇸Eugene, Oregon, United States
1218.40.10003 Boehringer Ingelheim Investigational Site
🇺🇸Chula Vista, California, United States
1218.40.10014 Boehringer Ingelheim Investigational Site
🇺🇸Spring Valley, California, United States
1218.40.42009 Boehringer Ingelheim Investigational Site
🇨🇿Brno, Czech Republic
1218.40.10021 Boehringer Ingelheim Investigational Site
🇺🇸Northglenn, Colorado, United States
1218.40.86001 Boehringer Ingelheim Investigational Site
🇨🇳Beijing, China
1218.40.38605 Boehringer Ingelheim Investigational Site
🇭🇷Krapinske Toplice, Croatia
1218.40.32001 Boehringer Ingelheim Investigational Site
🇧🇪Liège, Belgium
1218.40.36003 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1218.40.49101 Boehringer Ingelheim Investigational Site
🇩🇪Mainz, Germany
1218.40.54015 Boehringer Ingelheim Investigational Site
🇦🇷Parque Velez Sarfield, Argentina
1218.40.49028 Boehringer Ingelheim Investigational Site
🇩🇪Bad Mergentheim, Germany
1218.40.01010 Boehringer Ingelheim Investigational Site
🇨🇦Calgary, Alberta, Canada
1218.40.54011 Boehringer Ingelheim Investigational Site
🇦🇷Mendoza, Argentina
1218.40.32006 Boehringer Ingelheim Investigational Site
🇧🇪Edegem, Belgium
1218.40.32003 Boehringer Ingelheim Investigational Site
🇧🇪Gent, Belgium
1218.40.32002 Boehringer Ingelheim Investigational Site
🇧🇪Huy, Belgium
1218.40.01005 Boehringer Ingelheim Investigational Site
🇨🇦Calgary, Alberta, Canada
1218.40.30004 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1218.40.42004 Boehringer Ingelheim Investigational Site
🇨🇿Brno, Czech Republic
1218.40.38604 Boehringer Ingelheim Investigational Site
🇭🇷Slavonski Brod, Croatia
1218.40.49020 Boehringer Ingelheim Investigational Site
🇩🇪Dresden, Germany
1218.40.01006 Boehringer Ingelheim Investigational Site
🇨🇦Etobicoke, Ontario, Canada
1218.40.49007 Boehringer Ingelheim Investigational Site
🇩🇪Nürnberg, Germany
1218.40.30013 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1218.40.30006 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
1218.40.30016 Boehringer Ingelheim Investigational Site
🇬🇷Thessaloniki, Greece
1218.40.01001 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1218.40.49022 Boehringer Ingelheim Investigational Site
🇩🇪Berlin, Germany
1218.40.36006 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1218.40.97273 Boehringer Ingelheim Investigational Site
🇮🇱Haifa, Israel
1218.40.82002 Boehringer Ingelheim Investigational Site
🇰🇷Busan, Korea, Republic of
1218.40.30011 Boehringer Ingelheim Investigational Site
🇬🇷Piraeus, Greece
1218.40.42008 Boehringer Ingelheim Investigational Site
🇨🇿Hodonin, Czech Republic
1218.40.42003 Boehringer Ingelheim Investigational Site
🇨🇿Olomouc, Czech Republic
1218.40.82011 Boehringer Ingelheim Investigational Site
🇰🇷Daegu, Korea, Republic of
1218.40.36004 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1218.40.39006 Boehringer Ingelheim Investigational Site
🇮🇹Roma, Italy
1218.40.36005 Boehringer Ingelheim Investigational Site
🇭🇺Györ, Hungary
1218.40.49003 Boehringer Ingelheim Investigational Site
🇩🇪Neuwied, Germany
1218.40.49014 Boehringer Ingelheim Investigational Site
🇩🇪Saarbrücken, Germany
1218.40.97276 Boehringer Ingelheim Investigational Site
🇮🇱Safed, Israel
1218.40.81003 Boehringer Ingelheim Investigational Site
🇯🇵Suita, Osaka,, Japan
1218.40.97271 Boehringer Ingelheim Investigational Site
🇮🇱Jerusalem, Israel
1218.40.81001 Boehringer Ingelheim Investigational Site
🇯🇵Amagasaki, Hyogo, Japan
1218.40.81005 Boehringer Ingelheim Investigational Site
🇯🇵Koganei, Tokyo, Japan
1218.40.97272 Boehringer Ingelheim Investigational Site
🇮🇱Nahariya, Israel
1218.40.60001 Boehringer Ingelheim Investigational Site
🇲🇾Kuala Lumpur, Malaysia
1218.40.86013 Boehringer Ingelheim Investigational Site
🇨🇳Chengdu, China
1218.40.86009 Boehringer Ingelheim Investigational Site
🇨🇳Dalian, China
1218.40.86011 Boehringer Ingelheim Investigational Site
🇨🇳Guangzhou, China
1218.40.86014 Boehringer Ingelheim Investigational Site
🇨🇳Haerbin, China
1218.40.86008 Boehringer Ingelheim Investigational Site
🇨🇳Qingdao, China
1218.40.86002 Boehringer Ingelheim Investigational Site
🇨🇳Beijing, China
1218.40.86004 Boehringer Ingelheim Investigational Site
🇨🇳Beijing, China
1218.40.86015 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1218.40.86010 Boehringer Ingelheim Investigational Site
🇨🇳Shenyang, China
1218.40.86007 Boehringer Ingelheim Investigational Site
🇨🇳Wuhan, China
1218.40.86012 Boehringer Ingelheim Investigational Site
🇨🇳Wuhan, China
1218.40.86006 Boehringer Ingelheim Investigational Site
🇨🇳Xi'An, China
1218.40.42104 Boehringer Ingelheim Investigational Site
🇸🇰Bratislava, Slovakia
1218.40.88601 Boehringer Ingelheim Investigational Site
🇨🇳Taipei, Taiwan
1218.40.01002 Boehringer Ingelheim Investigational Site
🇨🇦London, Ontario, Canada
1218.40.01009 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1218.40.01012 Boehringer Ingelheim Investigational Site
🇨🇦Oakville, Ontario, Canada
1218.40.01008 Boehringer Ingelheim Investigational Site
🇨🇦Sarnia, Ontario, Canada
1218.40.20005 Boehringer Ingelheim Investigational Site
🇨🇦Strathroy, Ontario, Canada
1218.40.10002 Boehringer Ingelheim Investigational Site
🇺🇸Greer, South Carolina, United States
1218.40.10004 Boehringer Ingelheim Investigational Site
🇺🇸Simpsonville, South Carolina, United States
1218.40.10005 Boehringer Ingelheim Investigational Site
🇺🇸Dallas, Texas, United States
1218.40.54002 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1218.40.10009 Boehringer Ingelheim Investigational Site
🇺🇸Federal Way, Washington, United States
1218.40.54010 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1218.40.43001 Boehringer Ingelheim Investigational Site
🇦🇹Graz, Austria
1218.40.43005 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1218.40.32007 Boehringer Ingelheim Investigational Site
🇧🇪Brussel, Belgium
1218.40.32005 Boehringer Ingelheim Investigational Site
🇧🇪Brugge, Belgium
1218.40.32004 Boehringer Ingelheim Investigational Site
🇧🇪Genk, Belgium
1218.40.01003 Boehringer Ingelheim Investigational Site
🇨🇦Vancouver, British Columbia, Canada
1218.40.49024 Boehringer Ingelheim Investigational Site
🇩🇪Bosenheim, Germany
1218.40.36008 Boehringer Ingelheim Investigational Site
🇭🇺Debrecen, Hungary
1218.40.91012 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1218.40.91009 Boehringer Ingelheim Investigational Site
🇮🇳Hyderabad, Andra Pradesh, India
1218.40.91001 Boehringer Ingelheim Investigational Site
🇮🇳Kerala, India
1218.40.91011 Boehringer Ingelheim Investigational Site
🇮🇳Maharashtra, India
1218.40.91008 Boehringer Ingelheim Investigational Site
🇮🇳Mangalore, India
1218.40.97275 Boehringer Ingelheim Investigational Site
🇮🇱Holon, Israel
1218.40.97274 Boehringer Ingelheim Investigational Site
🇮🇱Afula, Israel
1218.40.97278 Boehringer Ingelheim Investigational Site
🇮🇱Tel Aviv, Israel
1218.40.39008 Boehringer Ingelheim Investigational Site
🇮🇹Genova, Italy
1218.40.39002 Boehringer Ingelheim Investigational Site
🇮🇹Milano, Italy
1218.40.39001 Boehringer Ingelheim Investigational Site
🇮🇹Pisa, Italy
1218.40.81004 Boehringer Ingelheim Investigational Site
🇯🇵Shinjyuku-ku,Tokyo, Japan
1218.40.82010 Boehringer Ingelheim Investigational Site
🇰🇷Jeonju, Korea, Republic of
1218.40.82008 Boehringer Ingelheim Investigational Site
🇰🇷Incheon, Korea, Republic of
1218.40.82001 Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
1218.40.82006 Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
1218.40.82007 Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
1218.40.82009 Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
1218.40.60003 Boehringer Ingelheim Investigational Site
🇲🇾Kelantan, Malaysia
1218.40.60002 Boehringer Ingelheim Investigational Site
🇲🇾Kuala Lumpur, Malaysia
1218.40.60007 Boehringer Ingelheim Investigational Site
🇲🇾Penang, Malaysia
1218.40.60004 Boehringer Ingelheim Investigational Site
🇲🇾Perak, Malaysia
1218.40.52007 Boehringer Ingelheim Investigational Site
🇲🇽Aguascalientes, Ags., Mexico
1218.40.52010 Boehringer Ingelheim Investigational Site
🇲🇽Col.Americana, Guadalajara, Jalisco, Mexico
1218.40.52006 Boehringer Ingelheim Investigational Site
🇲🇽Faccionamiento Lomas de Campestre,AGUASCAL, Mexico
1218.40.52008 Boehringer Ingelheim Investigational Site
🇲🇽Colonia Tlalpan, mexico, Mexico
1218.40.52001 Boehringer Ingelheim Investigational Site
🇲🇽Monterrey N.L., Mexico
1218.40.52003 Boehringer Ingelheim Investigational Site
🇲🇽Monterrey, Mexico
1218.40.52009 Boehringer Ingelheim Investigational Site
🇲🇽León, Mexico
1218.40.52002 Boehringer Ingelheim Investigational Site
🇲🇽México, Mexico
1218.40.52005 Boehringer Ingelheim Investigational Site
🇲🇽México, Mexico
1218.40.52004 Boehringer Ingelheim Investigational Site
🇲🇽México, Mexico
1218.40.31006 Boehringer Ingelheim Investigational Site
🇳🇱Deurne, Netherlands
1218.40.31001 Boehringer Ingelheim Investigational Site
🇳🇱Ewijk, Netherlands
1218.40.31010 Boehringer Ingelheim Investigational Site
🇳🇱Losser, Netherlands
1218.40.64003 Boehringer Ingelheim Investigational Site
🇳🇿Dunedin, New Zealand
1218.40.31008 Boehringer Ingelheim Investigational Site
🇳🇱Roelofarendsveen, Netherlands
1218.40.31002 Boehringer Ingelheim Investigational Site
🇳🇱Wildervank, Netherlands
1218.40.64004 Boehringer Ingelheim Investigational Site
🇳🇿Christchurch, New Zealand
1218.40.64001 Boehringer Ingelheim Investigational Site
🇳🇿Tauranga, New Zealand
1218.40.64002 Boehringer Ingelheim Investigational Site
🇳🇿Otahuhu, New Zealand
1218.40.64005 Boehringer Ingelheim Investigational Site
🇳🇿Wellington, New Zealand
1218.40.63005 Boehringer Ingelheim Investigational Site
🇵🇭Manila, Philippines
1218.40.63004 Boehringer Ingelheim Investigational Site
🇵🇭Quezon City, Philippines
1218.40.48603 Boehringer Ingelheim Investigational Site
🇵🇱Lublin, Poland
1218.40.63001 Boehringer Ingelheim Investigational Site
🇵🇭Pasig, Philippines
1218.40.48601 Boehringer Ingelheim Investigational Site
🇵🇱Warsaw, Poland
1218.40.48604 Boehringer Ingelheim Investigational Site
🇵🇱Zabrze, Poland
1218.40.40604 Boehringer Ingelheim Investigational Site
🇷🇴Brasov, Romania
1218.40.40603 Boehringer Ingelheim Investigational Site
🇷🇴Galati, Romania
1218.40.40505 Boehringer Ingelheim Investigational Site
🇷🇴Targu-Mures, Romania
1218.40.70014 Boehringer Ingelheim Investigational Site
🇷🇺Arkhangelsk, Russian Federation
1218.40.70001 Boehringer Ingelheim Investigational Site
🇷🇺Moscow, Russian Federation
1218.40.70002 Boehringer Ingelheim Investigational Site
🇷🇺Moscow, Russian Federation
1218.40.70013 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-on-Don, Russian Federation
1218.40.70005 Boehringer Ingelheim Investigational Site
🇷🇺Novosibirsk, Russian Federation
1218.40.70012 Boehringer Ingelheim Investigational Site
🇷🇺Moscow, Russian Federation
1218.40.70015 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1218.40.70004 Boehringer Ingelheim Investigational Site
🇷🇺Tomsk, Russian Federation
1218.40.42102 Boehringer Ingelheim Investigational Site
🇸🇰Bratislava, Slovakia
1218.40.42103 Boehringer Ingelheim Investigational Site
🇸🇰Banska Bystrica, Slovakia
1218.40.42101 Boehringer Ingelheim Investigational Site
🇸🇰Nove Mesto, Slovakia
1218.40.34002 Boehringer Ingelheim Investigational Site
🇪🇸Badalona, Spain
1218.40.42106 Boehringer Ingelheim Investigational Site
🇸🇰Samorin, Slovakia
1218.40.34011 Boehringer Ingelheim Investigational Site
🇪🇸Badia del Vallés, Spain
1218.40.34012 Boehringer Ingelheim Investigational Site
🇪🇸Borges del Camp, Spain
1218.40.34008 Boehringer Ingelheim Investigational Site
🇪🇸L'Hospitalet de Llobregat (Barcelona), Spain
1218.40.34007 Boehringer Ingelheim Investigational Site
🇪🇸Granada, Spain
1218.40.34004 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1218.40.34009 Boehringer Ingelheim Investigational Site
🇪🇸L'Hospitalet de Llobregat (Barcelona), Spain
1218.40.34014 Boehringer Ingelheim Investigational Site
🇪🇸Vic (Barcelona), Spain
1218.40.34010 Boehringer Ingelheim Investigational Site
🇪🇸Sant Adrià del Besós (Barcelona), Spain
1218.40.46013 Boehringer Ingelheim Investigational Site
🇸🇪Härnösand, Sweden
1218.40.46001 Boehringer Ingelheim Investigational Site
🇸🇪Malmö, Sweden
1218.40.46012 Boehringer Ingelheim Investigational Site
🇸🇪Uddevalla, Sweden
1218.40.88605 Boehringer Ingelheim Investigational Site
🇨🇳ChangHua, Taiwan
1218.40.46004 Boehringer Ingelheim Investigational Site
🇸🇪Uppsala, Sweden
1218.40.88604 Boehringer Ingelheim Investigational Site
🇨🇳Taichung, Taiwan
1218.40.88607 Boehringer Ingelheim Investigational Site
🇨🇳Taipei, Taiwan
1218.40.88602 Boehringer Ingelheim Investigational Site
🇨🇳Taipei, Taiwan
1218.40.38002 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
1218.40.88608 Boehringer Ingelheim Investigational Site
🇨🇳Taoyuan, Taiwan
1218.40.38011 Boehringer Ingelheim Investigational Site
🇺🇦Dnepropetrovsk, Ukraine
1218.40.66001 Boehringer Ingelheim Investigational Site
🇹🇭Bangkok, Thailand
1218.40.38004 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
1218.40.38001 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1218.40.38010 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
1218.40.38005 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1218.40.38009 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1218.40.38008 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1218.40.38003 Boehringer Ingelheim Investigational Site
🇺🇦Lvov, Ukraine
1218.40.38012 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1218.40.38007 Boehringer Ingelheim Investigational Site
🇺🇦Zaporizhzhya, Ukraine
1218.40.44004 Boehringer Ingelheim Investigational Site
🇬🇧Baillieston, Glasgow, United Kingdom
1218.40.38006 Boehringer Ingelheim Investigational Site
🇺🇦Vinnitsa, Ukraine
1218.40.44001 Boehringer Ingelheim Investigational Site
🇬🇧Bath, United Kingdom
1218.40.44005 Boehringer Ingelheim Investigational Site
🇬🇧Ashford, United Kingdom
1218.40.44003 Boehringer Ingelheim Investigational Site
🇬🇧Burbage, United Kingdom
1218.40.44009 Boehringer Ingelheim Investigational Site
🇬🇧Cardiff, United Kingdom
1218.40.44002 Boehringer Ingelheim Investigational Site
🇬🇧Penarth, United Kingdom
1218.40.44006 Boehringer Ingelheim Investigational Site
🇬🇧Reading, United Kingdom
1218.40.44010 Boehringer Ingelheim Investigational Site
🇬🇧Bury St Edmonds, United Kingdom
1218.40.44007 Boehringer Ingelheim Investigational Site
🇬🇧Waterloo, Liverpool, United Kingdom
1218.40.81002 Boehringer Ingelheim Investigational Site
🇯🇵Osaka, Osaka, Japan
1218.40.82003 Boehringer Ingelheim Investigational Site
🇰🇷Suwon, Korea, Republic of
1218.40.82005 Boehringer Ingelheim Investigational Site
🇰🇷Seoul, Korea, Republic of
1218.40.36002 Boehringer Ingelheim Investigational Site
🇭🇺Szombathely, Hungary
1218.40.70006 Boehringer Ingelheim Investigational Site
🇷🇺Perm, Russian Federation
1218.40.34013 Boehringer Ingelheim Investigational Site
🇪🇸Centelles, Spain
1218.40.70003 Boehringer Ingelheim Investigational Site
🇷🇺Moscow, Russian Federation
1218.40.82004 Boehringer Ingelheim Investigational Site
🇰🇷Pusan, Korea, Republic of
1218.40.70016 Boehringer Ingelheim Investigational Site
🇷🇺Samara, Russian Federation
1218.40.34006 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1218.40.34005 Boehringer Ingelheim Investigational Site
🇪🇸Sevilla, Spain
1218.40.35805 Boehringer Ingelheim Investigational Site
🇫🇮Seinäjoki, Finland
1218.40.35802 Boehringer Ingelheim Investigational Site
🇫🇮Turku, Finland
1218.40.91014 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1218.40.40504 Boehringer Ingelheim Investigational Site
🇷🇴Alba Iulia, Romania
1218.40.40501 Boehringer Ingelheim Investigational Site
🇷🇴Bucharest, Romania
1218.40.91004 Boehringer Ingelheim Investigational Site
🇮🇳Mumbai, India
1218.40.91003 Boehringer Ingelheim Investigational Site
🇮🇳Nasik, India
1218.40.42105 Boehringer Ingelheim Investigational Site
🇸🇰Bratislava, Slovakia
1218.40.63003 Boehringer Ingelheim Investigational Site
🇵🇭Greenhills, San Juan, Philippines
1218.40.63002 Boehringer Ingelheim Investigational Site
🇵🇭Marikina, Philippines
1218.40.40503 Boehringer Ingelheim Investigational Site
🇷🇴Sibiu, Romania
1218.40.88606 Boehringer Ingelheim Investigational Site
🇨🇳Tainan, Taiwan
1218.40.66002 Boehringer Ingelheim Investigational Site
🇹🇭Khon Kaen, Thailand
1218.40.01007 Boehringer Ingelheim Investigational Site
🇨🇦Saskatoon, Saskatchewan, Canada
1218.40.42006 Boehringer Ingelheim Investigational Site
🇨🇿Breclav, Czech Republic
1218.40.35806 Boehringer Ingelheim Investigational Site
🇫🇮Helsinki, Finland
1218.40.35801 Boehringer Ingelheim Investigational Site
🇫🇮Kuopio, Finland
1218.40.35803 Boehringer Ingelheim Investigational Site
🇫🇮Oulu, Finland
1218.40.91006 Boehringer Ingelheim Investigational Site
🇮🇳Jaipur, India
1218.40.91013 Boehringer Ingelheim Investigational Site
🇮🇳Uttar Pradesh, India
1218.40.60005 Boehringer Ingelheim Investigational Site
🇲🇾Perak, Malaysia
1218.40.40502 Boehringer Ingelheim Investigational Site
🇷🇴Bucharest, Romania
1218.40.42007 Boehringer Ingelheim Investigational Site
🇨🇿Brno, Czech Republic
1218.40.91010 Boehringer Ingelheim Investigational Site
🇮🇳Andhra Pradesh, India
1218.40.91002 Boehringer Ingelheim Investigational Site
🇮🇳Bangalore, India
1218.40.91005 Boehringer Ingelheim Investigational Site
🇮🇳Bangalore, India
1218.40.91007 Boehringer Ingelheim Investigational Site
🇮🇳Manipal, India
1218.40.01011 Boehringer Ingelheim Investigational Site
🇨🇦Vancouver, British Columbia, Canada
1218.40.88603 Boehringer Ingelheim Investigational Site
🇨🇳Taipei, Taiwan
1218.40.10007 Boehringer Ingelheim Investigational Site
🇺🇸San Antonio, Texas, United States
1218.40.01004 Boehringer Ingelheim Investigational Site
🇨🇦Montague, Prince Edward Island, Canada